The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to understand how the opioid system is involved in eating behavior.
Condition or disease
Drug: NaloxoneDrug: Placebo
Obesity is associated with greater risk for cardiovascular disease (CVD), stroke, diabetes, and mortality, and is a heterogeneous condition with various causes and thus a diversity of intervention targets. Compulsive overeating afflicts 30% of people seeking obesity treatment and increases risk for CVD factors. This trial involves two participant visits to test whether opioid blockade (Day 1 or 2, depending on randomization), compared to placebo (Day 1 or 2, depending on randomization), will elicit common symptoms of opioid withdrawal, including nausea. Participants will receive each condition on separate days.
Reward-driven eating (RED; Epel, Tomiyama, Mason, et al., 2014) [ Time Frame: personality measure assessed pre-treatment ]
Total score on the RED questionnaire
Impulsivity [ Time Frame: personality measure assessed pre-treatment ]
Impulsivity (or low executive control) will be measured with a battery of cognitive tasks and likely combined into an aggregate score. The tasks are: Go/No-Go (Fillmore, Rush, & Hays, 2006), Emotional Stroop Task (EST; Smith & Waterman, 2003), N-Back Task (Svaldi et al., 2014), Delayed Discounting (DD; Koffarnus & Bickel, 2014).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Obese, as defined by BMI greater than or equal to 30
Self-reported binge eating as defined in DSM-5, in the last 4 weeks
If sexually active with men, must agree to use birth control until the final study visit is complete (e.g., barrier methods, oral contraceptive)
Subject must be able to complete written informed consent procedures and be able to comply with the requirements of the study.
Pregnant or breastfeeding
Severe hypotension (< 90/60 mmHg)
Recent or current use of vasoconstrictor or vasodilator medication
Current or history of diabetes
Allergies to any ingredients in naloxone hydrochloride
History of or current alcoholism or drug dependence
Bulimia Nervosa as defined in DSM 5
Current or past use of opiate-containing medications in the last 30 days
Plan to use opiate-containing medications during study participation period
Medical conditions that are contraindicated with intranasal procedures: Nasal septal abnormalities, nasal trauma, epistaxis, excessive nasal mucus, and intranasal damage caused by the use of substances (e.g., cocaine)
Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the subject or the quality of the data